The KLOW Blend is a four-peptide research compound containing GHK-Cu (Glycine-Histidine-Lysine Copper, 50mg), TB-500 (Thymosin Beta-4 analog, 10mg), BPC-157 (10mg), and KPV (Lysine-Proline-Valine, 10mg). Each component targets distinct biological pathways involved in tissue repair, immune modulation, and cellular regeneration, making this combination of interest in preclinical research examining multi-compound peptide activity.

GHK-Cu is a copper-binding tripeptide studied for its role in collagen synthesis, antioxidant enzyme upregulation, and gene expression modulation across a broad range of biological pathways. TB-500 is a synthetic Thymosin Beta-4 analog investigated for its effects on actin polymerization, cellular migration, and angiogenesis in tissue repair models. BPC-157 is a pentadecapeptide studied for its effects on nitric oxide pathways, VEGF expression, and tissue repair processes across multiple tissue types. KPV, a tripeptide fragment of alpha-MSH, is studied for its interaction with melanocortin receptors and its potential role in anti-inflammatory and intestinal mucosal protection research.

The KLOW Blend is referenced in research examining the intersection of regenerative peptide biology and inflammatory pathway modulation. Its four-compound composition provides researchers with a preclinical model for investigating combined extracellular matrix support, vascular remodeling, gastrointestinal protection, and innate immune regulation in a single experimental preparation.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.